Ding… ABBV to Target #1
Back in April of this year we did an NFTRH+ on BioPharma ABBV and its amazingly similar setup to 2016’s NFTRH+ pick, LRCX. The original target was noted as 84, which ABBV is still on track for. But in weekly NFTRH reports that target was subsequently adjusted to a less conservative 88 and a new interim target of 75 was added several weeks ago. Well, … Continue reading Ding… ABBV to Target #1